New challenges on HPV and molecular screening

• OC 09-01 • Risk stratification of high-risk human papillomavirus positive women: impact of cytology and HPV 16/18 genotyping See abstract > L. Louise Thomsen • OC 09-02 • Bayesian analysis of baseline risk of CIN2+ and CIN3+ by HPV genotype in a screening cohort of NILM and ASCUS subjects See abstract > T. Thomas Wright • OC 09-03 • Determination of the 5-year longitudinal negative predisctive value of the Aptima HPV test in a routine screening population in Germany See abstract > T. Thomas Iftner • OC 09-04 • HPV based screening of 1.2 million women and mega HPV laboratory processing in Turkey See abstract > M. Murat Gultekin • OC 09-05 • Prevalence of HPV and cytologic abnormalities in the BD HPV Onclarity study See abstract > M. Mark Stoler • OC 09-06 • Preliminary 48 month exit results from the HPV focal cervical cancer screening trial See abstract > A. Andrew Coldman • OC 09-07 • Cervical screening with an interval beyond five years requires different rescreen timing for HPV-negative and HPV-positive, triage negative women: fourteen years follow-up of the Dutch Pobascam trial See abstract > M. Marjolein Van Zummeren • OC 09-08 • Evaluation of P16/KI-67 dual stain and HPV16/18 genotyping in a large population of HPV-positive women See abstract > W. Walter Kinney • OC 09-09 • Low sensitivity of HC2 for cancer detection in older women in the artistic cohort See abstract > C. Clare Gilham • OC 09-10 • Introducing CAREHPV into a public sector screening program in El Salvador See abstract > K. Karla Alfaro